ArticleGeroScience2026
Statin therapy optimization in older adults: interim results of a randomized controlled trial of pharmacist-led pharmaceutical care.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statin optimization in older adults is increasingly relevant within the geroscience framework of cardiovascular ageing. This randomized controlled trial evaluated whether pharmacist-led pharmaceutical care improves lipid outcomes and statin adherence in community-dwelling older adults receiving primary care. A total of 99 patients aged 65 years or older on long-term statin therapy were randomized to usual care or structured pharmacist-led care delivered every 3 months. The primary outcome was change in low-density lipoprotein cholesterol at 6 months. Secondary outcomes included changes in other lipid parameters and dispensing-based adherence assessed by the proportion of days covered. The present analysis represents a pre-specified interim evaluation and was conducted on a per-protocol population with complete 6-month laboratory data. No statistically significant between-group difference in low-density lipoprotein cholesterol reduction was observed (adjusted difference -0.129 mmol/L, p = 0.385). Statin adherence was high and stable in both groups throughout follow-up, with 84-87% of patients meeting adherence thresholds and approximately 75-77% achieving perfect dispensing, consistent with an apparent ceiling effect. Exploratory sex-stratified analyses identified potential differences in lipid responses, but these were not statistically robust. In these highly adherent elderly populations, pharmacist-led pharmaceutical care was not associated with additional short-term improvement in LDL-C or dispensing-based adherence. The findings highlight the importance of baseline adherence when evaluating adherence-focused interventions in older adults.
Indexed as
Identifiers
42527727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.